发明名称 |
Modified beta-lactamases and methods and uses related thereto |
摘要 |
The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide. |
申请公布号 |
US9034602(B2) |
申请公布日期 |
2015.05.19 |
申请号 |
US201113699434 |
申请日期 |
2011.05.17 |
申请人 |
Synthetic Biologics, Inc. |
发明人 |
Koski Pertti;Airaksinen Ulla;Valimaki Katja |
分类号 |
C12N9/86;C12N9/78;A61K38/50;A61K45/06;A61K31/43;A61K31/545;A61K38/00 |
主分类号 |
C12N9/86 |
代理机构 |
Morgan, Lewis & Bockius LLP |
代理人 |
Morgan, Lewis & Bockius LLP |
主权项 |
1. A beta-lactamase, comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1 and a hydrophilic amino acid residue other than aspartic acid (D) at a position corresponding to position 276 according to Ambler classification, wherein:
the hydrophilic amino acid residue is arginine (R) and the beta-lactamase hydrolyzes ceftriaxone substantially more efficiently than a beta-lactamase of SEQ ID NO: 1 that has an aspartic acid (D) at a position corresponding to position 276 according to Ambler classification. |
地址 |
Rockville MD US |